INSIG2 and metabolic dysfunction-associated steatotic liver disease: In contrast, specific hepatic mTORC1 suppression via folliculin (FLCN) deletion safeguards against NAFLD/NASH by promoting TFE3-mediated lipid clearance and inhibiting de novo lipogenesis through TFE3-induced Insig2 expression [131].